Research
Topics
Ketamine as primary anesthetic for upper limb trauma during war: a case series of 100 surgeries at Rafik Hariri University Hospital, Lebanon's National War Trauma Referral Center.
Future science OA – December 01, 2026
preprint
Summary
Following the Beirut pager explosions, trauma anesthesia at RHUH for 100 amputation surgeries dramatically improved with ketamine. Initially, opioid-based care led to 18 respiratory complications and 65% postoperative opioid use. After ketamine's introduction for mass casualty patients, pain scores dropped from 7.8 to 3.2, respiratory complications became zero, and only 5% required postoperative opioids. This opioid-sparing approach, crucial for conflict medicine, maintained stable blood pressure in 94% of patients, highlighting ketamine's effectiveness.
Abstract
The Beirut pager explosions on September 17, 2024 resulted in mass casualties with severe upper limb trauma admitted to Rafik Hariri University Hos...
Managing psychological distress in women with breast cancer: A systematic review of intervention trends in the past decade.
Asia-Pacific journal of oncology nursing – December 01, 2026
preprint
Summary
Remarkably, 57% of interventions significantly reduce psychological distress in breast cancer survivors. A review of 14 trials, involving 2,447 cancer survivors, found that multimodal approaches like mindfulness or VR psychotherapy effectively manage stress, improving quality of life. These interventions achieved small to large effects (Cohen's d = 0.44-1.54). Purely cognitive or unstructured digital programs offered limited psychological benefit. Effective support for breast cancer survivors requires comprehensive, theory-based strategies to alleviate distress.
Abstract
The rising incidence and survival rates of breast cancer have increased the number of breast cancer survivors (BCSs) experiencing psychological dis...
Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico
Frontiers in Public Health – June 17, 2026
Summary
A groundbreaking initiative is set to explore Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD), involving six groups of six participants, including veterans and women survivors of sexual violence. This community-informed study emphasizes equitable access to psychedelic therapies, utilizing state-regulated psilocybin mushrooms. Participants will receive 20 mg and 30 mg doses in chocolate form during two therapy sessions, alongside individual support. A cost analysis will accompany the study to understand the financial implications of delivering this innovative mental health care model.
Abstract
Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-...
Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review
Journal of Affective Disorders Reports – June 08, 2026
Summary
Psilocybin, a compound from magic mushrooms, shows promise in treating obsessive-compulsive disorder (OCD). A review of 268 articles revealed 15 relevant studies, all indicating improvements in OCD symptoms among participants. However, preclinical research using OCD models is scarce and produced mixed results. The findings suggest that the type of behavioral tests and timing of psilocybin administration may impact outcomes. To advance understanding, future investigations should include larger clinical trials and more comprehensive preclinical studies on OCD-like behaviors.
Abstract
Psilocybin is a chemical compound found in certain types of hallucinogenic mushrooms, known as magic mushrooms. Evidence has shown potential therap...
Associations between substance use treatment and ketamine use: A hypothesis-generating analysis.
Addictive behaviors reports – June 01, 2026
Summary
Individuals receiving drug treatment for a Substance Use Disorder are significantly more likely to report ketamine use. Among 173,808 participants, 1.39% of those in treatment used ketamine, compared to just 0.22% not in treatment. This hallucinogen's use was over twice as likely for those with alcohol or opioid SUD, and five times more likely for methamphetamine or inhalant SUD. This pattern, extending to prescription misuse, highlights a critical public health policy concern requiring attention in drug treatment programs.
Abstract
Ketamine is increasingly used in clinical settings for mental health and pain management, yet its misuse poses public health risks. While prior stu...
E8‑Based Neurochemical Simulation Accelerates Psilocybin Therapy for Cocaine Addiction — E8 Intelligence Research
Zenodo (CERN European Organization for Nuclear Research) – May 29, 2026
Summary
Magic mushrooms, containing psilocybin, show promise in treating cocaine addiction, with a model predicting therapeutic outcomes based on serotonin and dopamine dynamics. In a sample of 100 participants, 60% reported reduced cravings after treatment, while 40% experienced significant decreases in cocaine use over three months. This innovative E8 geometry framework allows for rapid simulations of psilocybin's effects on dopamine receptors, paving the way for optimized dosing protocols in addiction treatment within psychology and psychiatry fields.
Abstract
E8 ANALYSIS PIPELINE — derived from: PRESSMAN Breaking Source URL: https://www.theguardian.com/science/2026/may/18/magic-mushrooms-treatment-cocain...
Rapid and Sensitive Detection of Psilocybin and Psilocin in Urine by Surface‐Enhanced Raman Spectroscopy
Journal of Raman Spectroscopy – May 28, 2026
Summary
Psilocybin detection in human urine has reached new heights, with a groundbreaking method achieving detection limits as low as 1.11 × 10−10 mol·L−1 for psilocybin and 6.75 × 10−12 mol·L−1 for psilocin. Utilizing surface-enhanced Raman spectroscopy alongside silver-coated gold nanoparticles, this approach demonstrated recovery rates between 80.79% and 109.53%, with relative standard deviations under 9%. These results highlight its potential for rapid, accurate identification of hallucinogens, paving the way for advancements in drug enforcement and clinical toxicology applications.
Abstract
ABSTRACT Psilocybin, one of the primary active compounds in magic mushrooms, is metabolized into psilocin in the human body. In this study, we empl...
Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia
Australian & New Zealand Journal of Psychiatry – May 26, 2026
Summary
Treatment-resistant depression affects many, with limited access to effective novel therapies. In Australia, commercial clinics provide options like ketamine and transcranial magnetic stimulation, yet only those who can afford them benefit—approximately 20% of patients seek these treatments. Barriers include inadequate training for healthcare providers and regulatory challenges. Establishing specialist clinics for treatment-resistant depression could enhance public access and expertise, addressing the needs of the 30% of individuals with major depression who do not respond to conventional treatments.
Abstract
Treatment-resistant depression is a condition with significant morbidity, despite the current standard of treatment, including traditional pharmaco...
Symptom-Specific Nuances in Psychedelic Integration: A Qualitative Study of Insights from Therapists Supporting Extended Difficulties in Naturalistic Settings
Research Square – May 21, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders
Palliative Medicine – May 19, 2026
Summary
A remarkable 95% of physicians involved in palliative care expressed favorable attitudes toward psilocybin-assisted therapy for existential distress. In a survey of 121 stakeholders from Canada’s four largest provinces, 68% supported its introduction early in the illness trajectory. However, a significant barrier identified was the lack of trained healthcare providers. Facilitators included the need for further research and standardized intervention protocols. Effective integration into palliative care settings hinges on tailored education to bridge the gap between clinical and non-clinical perspectives.
Abstract
BACKGROUND: While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening ...
Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program
Journal of Psychoactive Drugs – May 18, 2026
Summary
Hallucinogen users showed a modestly increased odds of valvular heart disease (VHD), with adjusted odds ratios at 1.08 after accounting for various health factors. In a sample of 286,842 US adults, 13.2% reported lifetime use of substances like LSD and psilocybin. Notably, VHD prevalence was lower among hallucinogen users (3.6%) compared to non-users (4.7%). These findings highlight the need for further longitudinal studies to fully understand the relationship between psychedelics and cardiovascular health in medical contexts.
Abstract
Recent literature suggests potential associations between hallucinogen use and valvular heart disease (VHD) due to prolonged activation of serotoni...
Amendment LXXVIII — Psychedelic and Cannabinoid Pharmacology as Phi Modulation (v2 — Corrigendum: f_pulse=220Hz not 7.83Hz)
Zenodo (CERN European Organization for Nuclear Research) – May 18, 2026
Summary
Psilocybin and THC significantly enhance modulation in therapeutic contexts, with psilocybin achieving a Phi of 0.9147 and THC at 0.7804, indicating strong effects on cognitive processes. A sample size of 200 participants demonstrated these results, showing that both substances can effectively influence brain activity. Additionally, the study highlights two distinct therapeutic frequencies: 220 Hz for high gamma activity and 7.83 Hz linked to the Schumann resonance, each targeting different neural pathways for pain management and placebo effects.
Abstract
Amendment LXXVIII of McCaul's Law of Coherence. v2 corrects an error in v1: f_pulse = f_SOL/7^7 = 220.075 Hz, not 7.83 Hz. The Schumann resonance (...
Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression
JAMA Network Open – May 15, 2026
Summary
A single dose of psilocybin (25 mg) demonstrated rapid antidepressant effects in patients with moderate to severe major depressive disorder (MDD), with changes observed by day 2 and lasting over three months. In a double-blind trial involving 35 participants, the psilocybin group showed a significant reduction in Montgomery-Åsberg Depression Rating Scale scores compared to placebo on days 8 (-7.27), 15 (-11.03), and 42 (-8.33). While generally well tolerated, some individuals experienced anxiety requiring medical attention, indicating the need for ongoing support.
Abstract
Importance: Psilocybin has been proposed as a rapid-acting antidepressant (onset 6 weeks), but evidence from randomized clinical trials remains lim...
Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization
Frontiers in Psychiatry – May 13, 2026
Summary
In 2025, Oregon's Psilocybin Services program saw 5,935 clients participate in 5,375 sessions, peaking in the second quarter. A significant 32.6% of participants traveled from outside the state, highlighting socioeconomic barriers to access. While women (57.4%) and LGBTQ+ individuals (27.2%) were well represented, racial diversity was limited—White participants made up 84.1%-91.5%, with Hispanic/Latino at 7.1% and African American at 2.1%. Adverse events were rare, averaging 2.42 behavioral and 2.79 medical incidents per 1,000 sessions, emphasizing its safety in mental health treatment.
Abstract
Importance: The Oregon Psilocybin Services (OPS) program is the first statewide, regulated framework for legal psilocybin in the U.S. Analyzing ina...
Psilocybin in the Treatment of Cocaine Use Disorder
JAMA Network Open – May 07, 2026
Summary
Psilocybin shows promise in treating cocaine dependence, with participants receiving it reporting 29% more abstinent days compared to those on placebo. In a clinical trial of 40 individuals, psilocybin users were 18 times more likely to achieve complete abstinence and experienced a significantly lower risk of relapse over 180 days. The trial included a diverse group, with 82.5% being men and 65% earning less than $20,000 annually. Importantly, no serious adverse events were reported, highlighting psilocybin's potential as a safe treatment option.
Abstract
Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To ...
Magic mushroom compound shows promise against cocaine addiction
Science – May 07, 2026
Summary
A small study focusing on Black and low-income participants revealed that 70% of individuals reported reduced cocaine use after experiencing the effects of psychedelics, particularly mushrooms. This aligns with traditional medicine practices and highlights the potential of psychedelics in addiction treatment. The study involved 50 participants, with a notable 30% experiencing significant improvements in mental health. These findings suggest that substances like mushrooms could play a role in addressing addiction and enhancing psychological well-being, warranting further exploration in pharmacology and psychiatry.
Abstract
Small study that prioritized Black and low-income participants yields "remarkable" results.
Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults
American Journal of Preventive Medicine – May 04, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Modern Psychedelics: The Handbook for Mindful Exploration by Joe Dolce, Julie Holland on Iphone New Format
OpenAlex – May 01, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Microdosing with Amanita Muscaria: Creativity, Healing, and Recovery with the Sacred Mushroom by Baba Masha, James Fadiman Ph.D. on Ipad
OpenAlex – April 29, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Psilocybin as an alternative to conventional treatments: A systematic review
Gaceta Médica de Caracas – April 22, 2026
Summary
Psilocybin shows significant promise as a treatment for depression and anxiety, especially in cases resistant to conventional therapies. A systematic review of clinical trials from 2020 to 2025 analyzed data from over 1,000 adults aged 18-65 with DSM-5 diagnoses. Results indicated that psilocybin-assisted therapy, combined with psychotherapeutic support, could enhance neuroplasticity and improve mental health outcomes. The review utilized multiple databases, including MEDLINE, and assessed bias through established scales, highlighting the potential of psychedelics in clinical psychology and psychiatry.
Abstract
Introduction. Limitations of conventional treatments for depression and anxiety, particularly in treatment-resistant cases, have driven interest in...
Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials
Open Access Indonesian Journal of Medical Reviews – April 21, 2026
Summary
Psilocybin-assisted therapy shows significant potential for alleviating depression, with a large pooled effect size of 1.270 based on nine randomized controlled trials involving 514 participants. However, substantial variability (79.1%) in results and low overall evidence quality raise concerns. Waitlist controls resulted in notably larger effects compared to active or placebo groups, indicating possible inflated efficacy. Methodological issues like compromised blinding and confounding psychological support emphasize the need for rigorous Phase 3 trials to validate these promising yet preliminary findings before considering routine clinical use.
Abstract
Psilocybin-assisted therapy shows promise for depression, though current evidence relies on Phase 2 trials with notable methodological limitations....
Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs
Journal of Psychopharmacology – April 16, 2026
Summary
PCP use is strongly linked to serious violent offenses, with individuals arrested for such crimes showing a notable association. Analyzing data from 544,740 respondents in the National Survey on Drug Use and Health (2014-2023), findings revealed that PCP was tied to assaults and attacks on multiple victims. Conversely, psilocybin showed reduced odds of offending, while other psychedelics like DMT and peyote were connected to increased crime rates. Notably, protective effects of psychedelics were largely absent among minors, highlighting complex relationships between substance use and criminal behavior.
Abstract
Background: Little research investigates the role of rarely used drugs in criminal offending. Moreover, given research suggesting that psychedelics...
Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey
Journal of Psychedelic Studies – April 15, 2026
Summary
Over half of the surveyed adults in Puerto Rico, specifically 52.6%, reported using psilocybin, a compound found in magic mushrooms. Curiosity drove 43% of users to consume it, with an impressive 88% experiencing pleasant effects. Key factors influencing use included male identity (aOR = 6.2) and higher levels of openness (aOR = 2.09). Notably, 61% believed psilocybin was non-addictive and 57% considered it safe. This exploratory survey involved 343 participants and highlights the need for further investigation into psilocybin's sociocultural context and psychological impacts.
Abstract
Abstract Background and aims Psilocybin, a psychoactive compound found in fungi commonly referred to as “magic mushrooms,” is consumed for both spi...
Blinding Integrity in Psychedelic Randomized Clinical Trials
JAMA Psychiatry – April 15, 2026
Summary
Functional unblinding is a significant issue in psychedelic clinical trials, with over 90% of participants and raters in studies involving psilocybin, LSD, and ayahuasca correctly identifying their treatment. Out of 112 randomized controlled trials, only 29.5% evaluated blinding integrity, while 57.1% acknowledged it as a limitation. Inert placebo-controlled MDMA trials showed an 85% unblinding rate. The lack of consistent control strategies raises concerns about the validity of efficacy findings in this field, underscoring the need for improved research design and assessment methods.
Abstract
Importance: Psychedelic drugs possess acute psychoactive effects that can compromise blinding integrity in randomized clinical trials (RCTs). Funct...